Paradigm Biopharma
0 followers
Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.
Org chart
Paul Rennie
Founder & Chairman
Paul Rennie
Collapse
Simon White
Director of Investor Relations
Michelle Coffey
Global Head of Regulatory Affairs
Donna Skerrett
Chief Medical Officer and Executive Director
Justin Cahill
Chief Financial Officer
Donna Skerrett M.D. Msc
Chief Medical Officer
Catherine Stapledon
R&d Translational Scientist
Jill Forrest
Clinical Operations Lead
Similar companies
AstraZeneca
210 followers
Novo Nordisk
216 followers
Bristol-Myers Squibb
163 followers
Takeda Pharmaceutical
101 followers
Boehringer Ingelheim
61 followers
Omnicell
20 followers
ICON
17 followers
Syneos Health
16 followers
NYU Langone Health
12 followers
Alkem Laboratories Ltd
8 followers
DispatchHealth
6 followers
Discover companies